What we accept
- Corrections. If something on the site is factually wrong, link the page and tell us what should change.
- Peer-reviewed literature. New papers on SR-17018, related compounds, or relevant pharmacology.
- Regulatory updates. Scheduling changes, agency advisories, court decisions affecting legality.
- Forensic alerts. CFSRE, EMCDDA, DEA, or similar public alerts about the orphine series in the unregulated supply.
- Lab or analytical data. Independently verified identity confirmation, purity measurements, or adulterant findings.
- Vendor incident reports. Documented adulteration, mislabeling, or contamination of vendor product. Include identifiable evidence (chromatogram, photo, batch).
- Site improvements. Suggestions for clarity, accessibility, additional pages we should add.
We do not publish vendor recommendations, sourcing guides, or affiliate-style content regardless of submission. See methodology for our standards.
How submissions are handled
- Every submission is reviewed by an editor against our hierarchy of evidence.
- If we use your submission, we'll credit you in the page changelog (anonymously if you prefer, or by name if you provide one).
- We may follow up by email if we need clarification or full-text access.
- We don't publish PII from submitters. Email addresses are used only for follow-up.
- If we decline a submission, we'll tell you why where possible.
Submit your tip
Alternative ways to reach us
If you have material that's too sensitive for a web form — for example, identifiable forensic data tied to a specific case, or a vendor-incident report involving a person still using — contact the editorial team directly. A secure inbox will be published on the methodology page on launch of the v1 byline.